Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CER 001

Next Previous
Drug Profile

CER 001

Alternative Names: CER-001; Cerenis HDL; Recombinant Human Apolipoprotein A-I; Recombinant Human Apolipoprotein A-I/Phospholipids complex

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cerenis Therapeutics
  • Developer ABIONYX Pharma; Academic Medical Center
  • Class Antihyperlipidaemics; Apolipoprotein therapeutics; Cardiovascular therapies; Eye disorder therapies; Phospholipids; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Apolipoprotein A-I replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lecithin acyltransferase deficiency; Hypoalphalipoproteinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hypoalphalipoproteinaemia
  • Phase II Acute coronary syndromes; Acute kidney injury; Atherosclerosis
  • Preclinical Uveitis
  • No development reported COVID 2019 infections; Lecithin acyltransferase deficiency; Lipid metabolism disorders

Most Recent Events

  • 05 Mar 2025 CER 001 is available for licensing as of 05 Mar 2025 https://abionyx.com/en/
  • 28 Feb 2025 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in France (IV, Infusion)
  • 28 Jan 2025 No recent reports of development identified for preclinical development in Acute kidney injury in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top